Craft
Genexine

Genexine

Revenue

₩36.8 B

FY, 2021

Market Capitalization

₩630.9 B

2022-06-24

Genexine Summary

Company summary

Overview
Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics. It builds the hyFc technology, a proprietary platform designed to drive the discovery of differentiated protein therapeutics.
Type
Public
Founded
1999
HQ
Seongnam-si, KR | view all locations
Website
http://www.genexine.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

LocationsView all

2 locations detected

  • Seongnam-si, Gyeonggi-do HQ

    Korea (Republic of)

  • New York, NY

    United States

    Lefcourt Colonial Building, 295 Madison Ave #1201

Genexine Financials

Summary financials

Revenue (Q1, 2022)
₩10.8B
Gross profit (Q1, 2022)
₩12.0B
Net income (Q1, 2022)
₩16.2B
Cash (Q1, 2022)
₩36.2B
EBIT (Q1, 2022)
(₩15.9B)
Enterprise value
$652.4B

Footer menu